These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30218593)

  • 1. Detection of Angiotensin II type I-receptor antibodies in transplant glomerulopathy.
    Bussolino S; Dolla C; Ariaudo C; Civiletti F; Messina M; Mella A; Caorsi C; Amoroso A; Barreca A; Papotti M; Giunti S; Fop F; Biancone L
    Clin Transplant; 2018 Nov; 32(11):e13407. PubMed ID: 30218593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients.
    Fichtner A; Süsal C; Schröder C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Dragun D; Tönshoff B
    Nephrol Dial Transplant; 2018 Jun; 33(6):1065-1072. PubMed ID: 29444269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation.
    Gupta G; Fattah H; Ayalon R; Kidd J; Gehr T; Quintana LF; Kimball P; Sadruddin S; Massey HD; Kumar D; King AL; Beck LH
    Clin Transplant; 2016 Apr; 30(4):461-9. PubMed ID: 26854647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II Type 1 Receptor Expression in Renal Transplant Biopsies and Anti-AT1R Antibodies in Serum Indicates the Risk of Transplant Loss.
    Sas-Strózik A; Donizy P; Kościelska-Kasprzak K; Kamińska D; Gawlik K; Mazanowska O; Madziarska K; Hałoń A; Krajewska M; Banasik M
    Transplant Proc; 2020 Oct; 52(8):2299-2304. PubMed ID: 32448653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies.
    Taniguchi M; Rebellato LM; Cai J; Hopfield J; Briley KP; Haisch CE; Catrou PG; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Am J Transplant; 2013 Oct; 13(10):2577-89. PubMed ID: 23941128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies.
    Philogene MC; Bagnasco S; Kraus ES; Montgomery RA; Dragun D; Leffell MS; Zachary AA; Jackson AM
    Transplantation; 2017 Mar; 101(3):608-615. PubMed ID: 27222934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of AT1R antibody (AT1R-Ab) among Malaysian multi-ethnic population.
    Jalalonmuhali M; Caroll R; Deayton S; Emery T; Humphreys I; Lim SJ; Lim SK; Coates T
    Hum Immunol; 2020 Dec; 81(12):679-684. PubMed ID: 32736900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
    Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
    Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.
    Lim MA; Palmer M; Trofe-Clark J; Bloom RD; Jackson A; Philogene MC; Kamoun M
    Hum Immunol; 2017 Apr; 78(4):350-356. PubMed ID: 28284829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies Against ARHGDIB and ARHGDIB Gene Expression Associate With Kidney Allograft Outcome.
    Senev A; Otten HG; Kamburova EG; Callemeyn J; Lerut E; Van Sandt V; Kuypers D; Emonds MP; Naesens M
    Transplantation; 2020 Jul; 104(7):1462-1471. PubMed ID: 31651716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant Screening for Non-HLA Antibodies: Who should be Tested?
    Philogene MC; Zhou S; Lonze BE; Bagnasco S; Alasfar S; Montgomery RA; Kraus E; Jackson AM; Leffell MS; Zachary AA
    Hum Immunol; 2018 Apr; 79(4):195-202. PubMed ID: 29428484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
    Dragun D; Müller DN; Bräsen JH; Fritsche L; Nieminen-Kelhä M; Dechend R; Kintscher U; Rudolph B; Hoebeke J; Eckert D; Mazak I; Plehm R; Schönemann C; Unger T; Budde K; Neumayer HH; Luft FC; Wallukat G
    N Engl J Med; 2005 Feb; 352(6):558-69. PubMed ID: 15703421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.
    Halloran PF; Merino Lopez M; Barreto Pereira A
    Am J Transplant; 2016 Mar; 16(3):908-20. PubMed ID: 26743766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological analyses of transplant glomerulopathy cases.
    Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
    Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
    Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.